PRESS RELEASES - Cassava Sciences, Inc.
Sep 24, 2024 · Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates $207.3 Million in Cash and Cash Equivalents at June 30, 2024 . Company in Advanced Discussions to Resolve SEC Investigation. $40 Million Estimated Loss Contingency Recorded in Q2 for Resolution.
Cassava Sciences, Inc. (SAVA) Latest Stock News & Headlines
Get the latest Cassava Sciences, Inc. (SAVA) stock news and headlines to help you in your trading and investing decisions.
Controversial Alzheimer’s drug from Cassava Sciences fails ... - AAAS
Nov 25, 2024 · The biopharma company Cassava Sciences announced today its experimental Alzheimer’s disease drug simufilam showed no signs of working in a phase 3 clinical trial. Volunteers who took the drug performed no better in cognitive or everyday-life activities than those who received a placebo.
Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In …
Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ study of simufilam in mild-to-moderate Alzheimer’s disease.
Cassava shares sink on plans to stop Alzheimer's drug studies
Nov 25, 2024 · Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, sending shares of the drug developer plummeting 83% in early trading on Monday.
Cassava Sciences and its Alzheimer’s drug are done. The damage …
Nov 25, 2024 · Four years on, the Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, proving to be nothing more than a...
Cassava Sciences, Inc. (SAVA) Latest Press Releases & Corporate News …
Get the latest Cassava Sciences, Inc. (SAVA) stock news and headlines to help you in your trading and investing decisions.
No Decline in Cognition Scores in Patients with Mild Alzheimer's ...
AUSTIN, Texas, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today reported top-line results of a two-year clinical safety study of simufilam,...
After Cassava Alzheimer drug fiasco, FDA must protect patients
Oct 2, 2024 · For nearly a year, my stance on Cassava Sciences and its Alzheimer’s disease drug candidate simufilam has been clear: Emerging evidence shows the drug is inert, and patients with Alzheimer’s...
Cassava Sciences’ stock craters after Alzheimer’s disease trial fails ...
Nov 25, 2024 · Cassava Sciences Inc.’s stock tumbled 85% Monday to put it on track for its biggest-ever one-day decline, after the clinical-stage biotech company said a trial of a treatment for mild to...